Compare · AZYO vs CI
AZYO vs CI
Side-by-side comparison of Aziyo Biologics Inc. (AZYO) and The Cigna Group (CI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZYO and CI operate in Medical Specialities (Health Care), so they compete in similar markets.
- CI is the larger of the two at $78.25B, about 957.1x AZYO ($81.8M).
- CI has hit the wire 4 times in the past 4 weeks while AZYO has been quiet.
- CI has more recent analyst coverage (25 ratings vs 1 for AZYO).
- Company
- Aziyo Biologics Inc.
- The Cigna Group
- Price
- $1.49+2.05%
- $295.88+0.30%
- Market cap
- $81.8M
- $78.25B
- 1M return
- -
- +2.39%
- 1Y return
- -
- -4.59%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 0
- 4
- Recent ratings
- 1
- 25
Aziyo Biologics Inc.
Aziyo Biologics, Inc., a regenerative medicine company, focuses on the development of regenerative medical products to address the implantable electronic device/cardiovascular, orthopedic/spinal repair, and soft tissue reconstruction markets. It offers CanGaroo that combines the envelope with antibiotics and is designed to reduce the risk of infection following surgical implantation of an electronic device; and cardiovascular products, such as ProxiCor for use as an intracardiac patch or pledget for tissue repairs; Tyke for use in neonates and infants to repair pericardial structures; and VasCure, a patch material to repair or reconstruct the peripheral vasculature, including the carotid, renal, iliac, femoral, and tibial blood vessels for cardiovascular, vascular, and general surgeons. The company also provides FiberCel, ViBone, and OsterGro V that are designed to protect and preserve native bone cells; and SimpliDerm, a pre-hydrated HADM designed to repair or replacement of damaged or inadequate integumental tissues. In addition, it offers contract manufacturing services for various products to corporate customers. The company sells its products to hospitals and other healthcare facilities through its direct sales force, commercial partners, and independent sales agents. Aziyo Biologics, Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.
The Cigna Group
Cigna Corporation provides insurance and related products and services in the United States. Its Evernorth segment provides a range of coordinated and point solution health services, including pharmacy, benefits management, care, and intelligence solutions to health plans, employers, government organizations, and health care providers. The company's U.S. Medical segment offers commercial products and services, including medical, pharmacy, behavioral health, dental, vision, health advocacy programs, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as Medicaid plans; and individual health insurance plans to on and off the public exchanges. Its International Markets segment offers health coverage, hospitalization, dental, critical illness, personal accident, term life, medical cost containment, and variable universal life products, as well as health care benefits to mobile employees of multinational organizations. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.
Latest AZYO
- SEC Form SC 13G filed by Aziyo Biologics Inc.
- SEC Form 424B3 filed by Aziyo Biologics Inc.
- SEC Form SC 13G/A filed by Aziyo Biologics Inc. (Amendment)
- SEC Form 4 filed by Mills C Randal
- SEC Form 4 filed by Ferguson Matthew
- SEC Form 4 filed by Williams Michelle Leroux
- Aziyo Biologics Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits
- SEC Form S-8 filed by Aziyo Biologics Inc.
- Aziyo Biologics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- Aziyo Biologics Inc. filed SEC Form 8-K: Other Events
Latest CI
- EVP, Global CIO Koka Durga Prasad covered exercise/tax liability with 729 shares, decreasing direct ownership by 10% to 6,552 units (SEC Form 4) (withholding tax)
- SEC Form 4 filed by Director Kurian George
- The Cigna Group downgraded by Barclays with a new price target
- The Cigna Group downgraded by Deutsche Bank with a new price target
- Chairman & CEO Cordani David exercised 212,543 shares at a strike of $170.34 and sold $59,114,186 worth of shares (201,878 units at $292.82) as part of a pre-agreed trading plan, increasing direct ownership by 23% to 57,766 units (SEC Form 4)
- The Cigna Group filed SEC Form 8-K: Regulation FD Disclosure
- The Cigna Group Announces Appearance at the BofA Securities 2026 Health Care Conference
- Kayne Anderson Energy Infrastructure Fund Announces Appointment of Michael J. Hennigan as New Independent Director
- SEC Form 144 filed by The Cigna Group
- SEC Form 10-Q filed by The Cigna Group